A CALLG2008 protocol was developed by the Chinese Acute Lymphoblastic Leukemia Cooperative Group for adult acute lymphoblastic leukemia (ALL). We retrospectively analyzed 153 newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL enrolled into imatinib (400 mg/d) plus CALLG2008 regimen between 2009 and 2015. The median age was 40 years (range, 18-68 years), with 81 (52.3%) males. The overall hematologic complete remission (CR) rate was 96.7% after induction. With a median follow-up of 24.2 months, the estimated 3-year overall survival (OS) and event-free survival (EFS) rates were 49.5%(95%confidence interval (CI): 38.5%-59.5%) and 49.2% (95% CI: 38.3%-59.2%), respectively. Fifty-eight (36 with haploidentical donor) patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first CR. Among the patients in CR1 after induction, both the 3-year OS and EFS were significantly better in the allo-HSCT group than in the without allo-HSCT group (73.2%, 95% CI: 58.3%-83.5% vs. 22.2%, 95% CI: 8.7%-39.6% and 66.5%, 95% CI: 50.7%-78.2% vs. 16.1%, 95% CI: 5.1%-32.7%, respectively). Multivariate analysis showed that allo-HSCT and achievement of major molecular response were associated with favorable OS or EFS independently. Interestingly, in the allo-HSCT cohort, the donor type (haploidentical versus matched donors) had no significant impact on EFS or OS. All these results suggested that imatinib plus CALLG2008 was an effective protocol for Ph-positive ALL. Haploidentical donors can also be a reasonable alternative expedient donor pool.
Background The study aimed to investigate the correlation between both particulate matter (PM) 2.5 and temperature and the incidence of severe asthma as diagnosed by fractional exhaled nitric oxide (FeNO) values of >50 parts per billion. Methods This large-scale retrospective study used data on PM2.5 and temperature from the Shanghai Meteorological Bureau in China that had been collected between May 2014 and April 2016. All patients with suspected airway inflammation, who had visited the Minhang branch of Zhongshan Hospital, an affiliation of Fudan University, between May 2014 and April 2016, were retrospectively enrolled in this study. Spearman’s rank correlation coefficient and multiple linear regression models were used to analyze the synergistic effect of PM2.5 and temperature on the incidence of severe asthma in the different subgroups of patients with suspected airway inflammation. Results PM2.5 and temperature were significantly correlated with the incidence of asthma in the Oldabove50 subgroup (Spearman’s r = 0.580, p = 0 .003 and Spearman’s r = -0.689, p ≤ 0.001, respectively), when analyzed using non-parametric statistical analysis methods. The combined effect of PM2.5 and temperature on the incidence of asthma was significantly greater in the Oldabove50 subgroup (R = 0.693) than in the Adultabove50 subgroup (R = 0.275) (F > Fα; Fα = 2.997066, p < 0.05). In particular, in the Oldabove50 subgroup, the effect of temperature on the incidence of asthma was greater than that of PM2.5, when using beta coefficients (p = 0.004). Conclusions The FeNO cut-off value can be used to determine the effect of PM2.5 and temperature on patients’ respiratory health. Although the study’s limitations may have impacted these findings, and further investigation is necessary, this study provided a convenient investigation into the epidemiology of asthma. Such research is important for public health.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.